Please ensure Javascript is enabled for purposes of website accessibility

Why MannKind Corp. Stock Fell 15.7% in September

By Cory Renauer - Updated Oct 11, 2016 at 8:04AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

MannKind's investors added potential exchange delisting to a growing stack of problems.

Image source: Getty Images.

What happened

Shares of MannKind Corp. (MNKD 2.58%), a struggling diabetes care company, fell 15.7% in October, according to data from S&P Global Market Intelligence. Waiting eight days to inform shareholders it received a warning letter from the Nasdaq exchange didn't sit well with the market.

MNKD Chart

MNKD data by YCharts

So what 

On Sept. 22, MannKind Corp. announced that it had received a warning letter from Nasdaq on Sept. 14. The troubled company's stock price had closed below the $1-per-share minimum required by the exchange's listing rules for 30 consecutive days. 

MannKind stock's noncompliance with the minimum requirement was hardly a surprise, but dragging its feet before announcing the notice is troubling. The exchange requires companies to notify shareholders of these types of notices within four business days after receiving them. MannKind acknowledged that it informed Nasdaq it failed to meet this requirement on day five, and then filed the announcement with the U.S. Securities and Exchange Commission on day six.

Without any explanation for the delay, many assumed the company was waiting for some encouraging signs from its last-ditch effort to relaunch inhalable insulin device Afrezza, but had none to offer.

Now what

MannKind's stock price needs to close above the $1 minimum for at least 10 consecutive days during the 180-day period that began the day it received the notice, or it could face delisting from the Nasdaq exchange. MannKind shares also trade on the Tel Aviv exchange, but a Nasdaq delisting would still make raising enough equity to fund its operations nearly impossible. The company burned through $29.96 million during the three months ended June, finishing the quarter with just $63.7 million in cash and equivalents.

MannKind could meet the minimum price with a reverse stock split, but that would hardly solve all its problems. If this company is to remain solvent, Afrezza needs to start flying off pharmacy shelves immediately. It finished June with liabilities to be repaid within one year of $289.7 million, against assets available to meet those obligations of just $90.8 million. Additional red flags on the company's balance sheet will make climbing out of this hole especially difficult. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

MannKind Corporation Stock Quote
MannKind Corporation
MNKD
$3.77 (2.58%) $0.10

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.